Biomarin Pharmaceutical Inc. is considering the design to be sought for the pivotal phase III trial with BMN 111 (vosoritide), an analog of C-type natriuretic peptide (CNP), in children with achondroplasia, thanks to strong results with the highest of three doses – 15 µg/kg/daily – in a phase II experiment that enrolled 26 children with a mean age of 7.8 years.